Last reviewed · How we verify
IMO-8400 Regimen 2
IMO-8400 is a small molecule inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway.
IMO-8400 is a small molecule inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | IMO-8400 Regimen 2 |
|---|---|
| Sponsor | Idera Pharmaceuticals, Inc. |
| Drug class | IRAK4 inhibitor |
| Target | IRAK4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting IRAK4, IMO-8400 aims to reduce inflammation and modulate the immune response. This mechanism is being explored for its potential to treat various inflammatory and autoimmune diseases.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMO-8400 Regimen 2 CI brief — competitive landscape report
- IMO-8400 Regimen 2 updates RSS · CI watch RSS
- Idera Pharmaceuticals, Inc. portfolio CI